What question did this study set out to answer?

The study aims to assess the long-term safety, tolerability, and efficacy of bexicaserin in participants with developmental and epileptic encephalopathies.

June 13, 2026Neurology

Primary Results of the 12-month Open-label Extension of the Phase 1b/2a PACIFIC Trial of Bexicaserin for the Treatment of Seizures in Participants with Developmental and Epileptic Encephalopathies Demonstrates Long-term Safety, Tolerability, and Efficacy (P11-10.004)

View Full Paper

Ask AI

Bookmark

Authors

DDDennis J. DlugosChildren's Hospital of Philadelphia ISIngrid E. SchefferRoyal Children's Hospital JFJacqueline A. FrenchNew York University

Discussion

Member takes

Implication

Open-label extension trial evaluates the safety and efficacy of bexicaserin in participants with DEEs, suggesting positive outcomes.

Key Points

The study aims to assess the long-term safety, tolerability, and efficacy of bexicaserin in participants with developmental and epileptic encephalopathies.
Conducted an open-label extension of the Phase 1b/2a PACIFIC trial
Participants included those with developmental and epileptic encephalopathies
Evaluated safety and efficacy over 12 months
Bexicaserin demonstrated a favorable safety profile with no serious adverse events reported
Participants showed improved seizure control and tolerability throughout the study duration

Cite This Study

Dlugos et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f05614e https://doi.org/10.1212/wnl.0000000000215386

View Full Paper

Ask AI

Bookmark

Primary Results of the 12-month Open-label Extension of the Phase 1b/2a PACIFIC Trial of Bexicaserin for the Treatment of Seizures in Participants with Developmental and Epileptic Encephalopathies Demonstrates Long-term Safety, Tolerability, and Efficacy (P11-10.004)

Discussion

Member takes

Implication

Key Points

Cite This Study

Primary Results of the 12-month Open-label Extension of the Phase 1b/2a PACIFIC Trial of Bexicaserin for the Treatment of Seizures in Participants with Developmental and Epileptic Encephalopathies Demonstrates Long-term Safety, Tolerability, and Efficacy (P11-10.004)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider